Single-Dose Psychedelic DMT Reduced Depressive Disorder Symptoms Within Two Weeks

A short-duration psychedelic medication N,N-Dimethyltryptamine (DMT) significantly reduced symptoms of major depressive disorder (MDD) within two weeks. The remission rate was 57% at 12 weeks. In a two-week trial, the single-dose intravenous medication was tested against a single-dose intravenous placebo. In the first week the remission rate was 44% for the treatment group and 13% for the placebo group. Both groups received ongoing supportive therapy.

The medication is an intravenous form of DMT, which producer Small Pharma refers to as SPL026. In the Phase IIa clinical trial, the researchers tested SPL026 in one dose . . .